Fig. 2
FGF19ΔKLB protected against intrahepatic cholestasis brought on with ANIT. For six days, intraperitoneal injections of PBS, FGF19 (1.0 mg/kg), or FGF19ΔKLB (1.0 mg/kg) were given to male C57BL/6J mice that were eight weeks old. There were six mice per group. On the fourth day, mice were orally given ANIT in olive oil (75 mg/kg) to develop an intrahepatic cholestasis animal model. As a control, six C57BL/6J male mice were not treated with ANIT. (A-C) Analysis of serum alanine transaminase (ALT) (A), aspartate transaminase (AST) (B), and total BAs (C) levels. (D) FGF19WT and FGF19ΔKLB-treated mice exhibited a substantial reduce in the hepatic BA pool. (E-H) Hepatic genes expression of key enzymes in BA synthesis, including Cyp7a1 (E), Cyp8b1(F), Cyp27a1(G), and Cyp7b1(H), was analyzed by RT-PCR. (I) Representative H&E-stained liver tissues. Noted that vehicle-treated ANIT mice showed multifocal liver necrosis (dashed area), while liver tissues from FGF19ΔKLB-treated mice had minimal or no lesions